What Is Zepbound?

1. What Is Zepbound?

Zepbound is an injectable prescription medicine that contains tirzepatide. The current DailyMed label says Zepbound is indicated with reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight and at least one weight-related comorbid condition.

The same label also lists Zepbound for moderate to severe obstructive sleep apnea, or OSA, in adults with obesity. That second indication is easy to miss because public discussion often treats Zepbound only as a weight-management drug. The label is more specific than the headline.

2. Why Is Tirzepatide the Important Word?

Tirzepatide is the active ingredient in Zepbound. DailyMed’s Zepbound label describes tirzepatide as a GIP receptor and GLP-1 receptor agonist, and the clinical pharmacology section says it selectively binds to and activates both the GIP and GLP-1 receptors.

That distinction matters because brand names change the context. “Zepbound” tells you a brand and labeled use context. “Tirzepatide” tells you the molecule. “Dual GIP/GLP-1 receptor agonist” tells you the receptor-language category. Those are related facts, but they are not interchangeable.

If you want more background on confusing GLP terminology, see GLP-1 vs GLP-2 vs GLP-3. Zepbound is not a GLP-2 or GLP-3 product. The common shorthand is about GLP-1 and GIP receptor activity.

3. What Does Dual GIP/GLP-1 Mean?

Dual GIP/GLP-1 means tirzepatide is designed to activate two incretin-related receptor pathways: glucose-dependent insulinotropic polypeptide, usually shortened to GIP, and glucagon-like peptide-1, shortened to GLP-1. FDA’s chronic weight management announcement says Zepbound activates receptors for both hormones to reduce appetite and food intake.

That does not mean Zepbound is two separate medicines mixed together. It means one active ingredient, tirzepatide, has activity at two receptor targets. This is why some careful sources call it a dual GIP and GLP-1 receptor agonist instead of just a GLP-1.

The shortcut “GLP-1 drug” is still common because GLP-1 is the best-known public term. It is useful in casual conversation, but it hides the GIP part. In an explainer, label, or record, the fuller phrase is more precise.

4. How Is Zepbound Related to Mounjaro?

Zepbound and Mounjaro both contain tirzepatide, but they are not the same brand. FDA’s 2023 Zepbound announcement noted that tirzepatide was already approved under the trade name Mounjaro for use with diet and exercise to help improve blood sugar in adults with type 2 diabetes.

The current DailyMed Mounjaro label lists Mounjaro as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. The current DailyMed Zepbound label lists weight reduction, long-term weight maintenance, and OSA contexts.

That is the core relationship: same active ingredient, different brand and labeled context. A headline that says “the same drug” may be chemically understandable, but it can still be sloppy. Brand, indication, patient population, packaging, safety language, and payer rules can all matter.

For related brand context, the site also has separate pages for tirzepatide records, Mounjaro records, and Zepbound records. Those pages are about organizing records, not choosing treatment.

5. Where Does OSA Fit In?

FDA announced in December 2024 that Zepbound was approved for moderate to severe obstructive sleep apnea in adults with obesity, used with reduced-calorie diet and increased physical activity. The FDA release described it as the first drug treatment option for certain patients with OSA.

The OSA approval was based on two randomized, double-blind, placebo-controlled studies of 469 adults without type 2 diabetes. FDA said one study enrolled people using positive airway pressure therapy, and the other enrolled people unable or unwilling to use that therapy.

The measured endpoint was apnea-hypopnea index, or AHI, which counts apnea and hypopnea events per hour of sleep. FDA said participants receiving Zepbound had statistically significant and clinically meaningful AHI reductions compared with placebo, and the agency noted that improvement was likely related to body-weight reduction.

That last point is important. OSA is not just a new marketing word attached to the same story. It is a specific labeled context with specific study conditions. It also does not mean anyone should interpret sleep symptoms from a medication article.

6. Why Do Media Stories Get Zepbound Confusing?

Media stories get confusing because they usually optimize for the name readers recognize. “GLP-1,” “weight-loss shot,” “tirzepatide,” “Zepbound,” and “Mounjaro” may all appear in the same story, even when each word points to a different layer of the facts.

There are at least four layers. The molecule is tirzepatide. The brand may be Zepbound or Mounjaro. The receptor language is dual GIP/GLP-1. The labeled context may involve chronic weight management, type 2 diabetes, or moderate to severe OSA in adults with obesity.

Once those layers are mixed, several bad shortcuts appear. People may assume Zepbound and Mounjaro are interchangeable. They may assume “GLP-1” describes every mechanism detail. They may treat OSA approval as a general sleep-apnea claim. They may read trial averages as personal predictions.

The fix is not complicated. Ask which molecule, which brand, which label, which study population, and which source. Those five facts usually make the article much clearer.

7. What Facts Matter Most?

The facts that matter are the ones that keep language precise. Zepbound contains tirzepatide. Tirzepatide is described in the label as a GIP and GLP-1 receptor agonist. Zepbound has FDA-labeled contexts for chronic weight management and for moderate to severe OSA in adults with obesity.

Mounjaro also contains tirzepatide, but its label is centered on type 2 diabetes glycemic-control use. “Same active ingredient” is true, but it does not erase the brand and label distinction.

Clinical-trial numbers also need context. FDA’s chronic weight-management release described two 72-week trials with 2,519 participants receiving Zepbound and 958 receiving placebo. The larger trial enrolled adults without diabetes, and the FDA reported average body-weight loss of 18% for the highest approved dose group compared with placebo. That is a population result, not a personal forecast.

Safety facts matter too. FDA and DailyMed both list serious warnings and common adverse reactions that belong in source labeling rather than a brand-name explainer.

8. Sources

9. Zepbound FAQ

• What is Zepbound in simple terms?

  Zepbound is a prescription medicine that contains tirzepatide. FDA labeling says it is used with reduced-calorie diet and increased physical activity for long-term weight reduction in adults with obesity or certain adults with overweight, and for moderate to severe OSA in adults with obesity.

• Is Zepbound the same as Mounjaro?

  No. Zepbound and Mounjaro both contain tirzepatide, but they are different brands with different labeled contexts. DailyMed lists Zepbound for weight reduction and certain OSA use, while Mounjaro is listed for glycemic control in type 2 diabetes.

• Why is Zepbound called a dual GIP/GLP-1 medicine?

  The Zepbound label describes tirzepatide as a GIP receptor and GLP-1 receptor agonist. That means the molecule is designed to selectively bind and activate both receptor pathways, which is different from calling it only a GLP-1 drug.

• Is Zepbound approved for obstructive sleep apnea?

  Yes, within a specific labeled context. FDA announced in December 2024 that Zepbound was approved for moderate to severe obstructive sleep apnea in adults with obesity, used with reduced-calorie diet and increased physical activity.